Michael T. Stocum
Fondateur chez Personalized Medicine Partners LLC
Profil
Michael T.
Stocum is the founder of Personalized Medicine Partners LLC, which was founded in 2004.
He held the title of President at the company.
He currently holds the position of President & Chief Executive Officer at Bantam Pharmaceutical LLC since 2019.
He is also the Chairman-Personalized Medicine Division at the American Association for Clinical Chemistry, Inc. He has been a Director at BioFluidica, Inc. since 2015 and a Director at Mobility Health, Inc. In his former positions, Mr. Stocum served as the President & Chief Executive Officer of On-Q-ity, Inc. He was the Chief Executive Officer of Inivata Ltd.
from 2014 to 2018.
He also served as an Independent Director at Timber Pharmaceuticals, Inc. in 2020.
Additionally, he held positions at GlaxoWellcome, Xanthon, Inc., Merck, bioMérieux, Inc., GlaxoSmithKline Pharmaceuticals SA (Belgium), and Tricon Pharmaceuticals, Inc.Mr. Stocum completed his undergraduate and graduate degrees at North Carolina State University.
Postes actifs de Michael T. Stocum
| Sociétés | Poste | Début |
|---|---|---|
American Association for Clinical Chemistry, Inc.
 American Association for Clinical Chemistry, Inc. Medical/Nursing ServicesHealth Services American Association for Clinical Chemistry, Inc. (AACC) is a scientific and medical professional organization that focuses on clinical laboratory science and its application to healthcare. The organization is based in Washington and was founded in 1948. AACC provides leadership in education, advocacy, and collaboration to help lab professionals adapt to change and provide vital insight and guidance for patient care. The organization offers accreditation programs, press releases, media advisories, and statements that spotlight scientific, clinical, and technological breakthroughs. AACC has a longstanding commitment to provide customers with the best possible experience every time they use the AACC website. Mark J. Golden has been the CEO of the American company since 2020. | Corporate Officer/Principal | - |
BioFluidica, Inc.
 BioFluidica, Inc. Medical/Nursing ServicesHealth Services BioFluidica, Inc. is a biotechnology company specializing in the development of diagnostic platform for disease management. It captures and isolates disease biomarkers, such as Circulating Tumor Cells. The company was founded by Steven A. Soper in 2007 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/09/2015 |
| Personalized Medicine Partners LLC | Fondateur | 01/06/2004 |
Bantam Pharmaceutical LLC
 Bantam Pharmaceutical LLC BiotechnologyHealth Technology Bantam Pharmaceutical LLC is a privately funded biopharmaceutical company that specializes in the discovery and development of novel therapeutics for difficult-to-treat hematological and solid tumors. The company is based in New York, NY. The company is currently pursuing an IND application for its lead candidate, BTM-3566, in B-cell malignancies. Bantam's clinical development strategy is focused on areas of unmet clinical need, with initial phase I/II clinical trials planned in relapsed/refractory B-cell hematological malignancies, including diffuse large B-cell lymphoma. The company was founded by Victor F. Keen, and Michael T. Stocum has been the CEO of the company since 2019. | Directeur Général | 28/04/2021 |
| Mobility Health, Inc. | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael T. Stocum
| Sociétés | Poste | Fin |
|---|---|---|
| TREX WIND-DOWN, INC. | Directeur/Membre du Conseil | 19/08/2020 |
Inivata Ltd.
 Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Directeur Général | 08/05/2018 |
On-Q-ity, Inc.
 On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | Directeur Général | 14/01/2014 |
| Tricon Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Michael T. Stocum
| North Carolina State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TREX WIND-DOWN, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
On-Q-ity, Inc.
On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | Health Services |
| GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
GlaxoSmithKline Pharmaceuticals SA (Belgium)
 GlaxoSmithKline Pharmaceuticals SA (Belgium) Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium. | Health Technology |
| Merck/Schering-Plough Pharmaceuticals | |
bioMérieux, Inc.
 bioMérieux, Inc. Medical SpecialtiesHealth Technology bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC. | Health Technology |
Xanthon, Inc.
 Xanthon, Inc. Packaged SoftwareTechnology Services Part of Nokia Oyj, Xanthon, Inc. develops enterprise software solutions. The company is based in Research Triangle Park, NC. The company was founded by Clay Bernardin Thorp. Xanthon was acquired by Talk2 Technology, Inc. on June 14, 1999. | Technology Services |
| Tricon Pharmaceuticals, Inc. | |
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Technology Services |
American Association for Clinical Chemistry, Inc.
American Association for Clinical Chemistry, Inc. Medical/Nursing ServicesHealth Services American Association for Clinical Chemistry, Inc. (AACC) is a scientific and medical professional organization that focuses on clinical laboratory science and its application to healthcare. The organization is based in Washington and was founded in 1948. AACC provides leadership in education, advocacy, and collaboration to help lab professionals adapt to change and provide vital insight and guidance for patient care. The organization offers accreditation programs, press releases, media advisories, and statements that spotlight scientific, clinical, and technological breakthroughs. AACC has a longstanding commitment to provide customers with the best possible experience every time they use the AACC website. Mark J. Golden has been the CEO of the American company since 2020. | Health Services |
BioFluidica, Inc.
BioFluidica, Inc. Medical/Nursing ServicesHealth Services BioFluidica, Inc. is a biotechnology company specializing in the development of diagnostic platform for disease management. It captures and isolates disease biomarkers, such as Circulating Tumor Cells. The company was founded by Steven A. Soper in 2007 and is headquartered in San Diego, CA. | Health Services |
| Personalized Medicine Partners LLC | |
Bantam Pharmaceutical LLC
Bantam Pharmaceutical LLC BiotechnologyHealth Technology Bantam Pharmaceutical LLC is a privately funded biopharmaceutical company that specializes in the discovery and development of novel therapeutics for difficult-to-treat hematological and solid tumors. The company is based in New York, NY. The company is currently pursuing an IND application for its lead candidate, BTM-3566, in B-cell malignancies. Bantam's clinical development strategy is focused on areas of unmet clinical need, with initial phase I/II clinical trials planned in relapsed/refractory B-cell hematological malignancies, including diffuse large B-cell lymphoma. The company was founded by Victor F. Keen, and Michael T. Stocum has been the CEO of the company since 2019. | Health Technology |
| Mobility Health, Inc. |